MHR
SMMT icon

Matthew Hamilton Rosenberg’s Summit Therapeutics SMMT Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.47K Hold
501
– – ﹤0.01% 655
2026
Q2 		$7.3K Hold
501
– – ﹤0.01% 663
2026
Q1 		$9.5K Hold
501
– – ﹤0.01% 619
2025
Q4 		$8.76K Hold
501
– – ﹤0.01% 645
2025
Q3 		$10.4K Hold
501
– – ﹤0.01% 627
2025
Q2 		$10.7K Buy
+501
New +$11.4K ﹤0.01% 645

Other funds holding SMMT

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM

Matthew Hamilton Rosenberg's SMMT Position: Q3 2026 in Review

Matthew Hamilton Rosenberg held its Summit Therapeutics (SMMT) position steady in Q3 2026 at 501 shares worth $8.47K. The position accounts for ﹤0.01% of the portfolio, ranked #655.

Matthew Hamilton Rosenberg first reported a position in SMMT in Q2 2025 and has held it in 6 quarters since. The position peaked at $10.7K in Q2 2025. 10 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Matthew Hamilton Rosenberg held 501 shares of Summit Therapeutics worth $8.47K as of Q3 2026.
  • Matthew Hamilton Rosenberg left its Summit Therapeutics share count unchanged in Q3 2026.
  • Summit Therapeutics made up ﹤0.01% of Matthew Hamilton Rosenberg's portfolio in Q3 2026, its #655 holding.
  • Matthew Hamilton Rosenberg first reported a position in Summit Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Matthew Hamilton Rosenberg's Summit Therapeutics position peaked at $10.7K in Q2 2025.
  • 10 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Matthew Hamilton Rosenberg's 13F filing for Q3 2026, filed 5 Oct 2026.